CAMBRIDGE，Mass.--（BUSINESS WIRE）--Obsidian Therapeutics，Inc。，a clinical-stage biotechnology company pioneering engineered cell and gene therapies，today announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE®platform demonstrating regulable cytoTIL and dugns，as well as the ability of a single drug-responsive domain（DRD）to coregulate two cytokines，LIGHT and mbIL15，in tumor-infiltrating lymphocytes（TIL）during the American Association of Cancer Research（AACR）Annual Meeting，which will be held April5-102024in San Diego，CA。
These data follow theannouncement（1）从positive top-line results from the ongoing first-in-human，Phase1 clinical trial evaluating the safety and efficy of OBX-115，Obsidian’slead engineered TIL cell therapy candidate，in patients with metatic melanoma that has relapsed and/or is refractory to prior immuck checkpointer（ICbitor）NCT 05470283）。
The details of these posters are as follows:
标题：OBX-115engineered tumor-infiltrating lymphocyte（TIL）cell therapy induced deepening and durable responses withot interleukin2（IL2）in patients（pts）with immune checkpoint inhibitor（ICI）-resistant unresectable or metatic melanoma
Presenting Author:Rodabe N Amaria，The University of Texas MD Anderson Cancer Center，Houston，TX
后期：CT176，Tuesday April9,9:00 AM-12:30 PM PDT
标题：Trial in progress:Aphase1/2study to investigate the safety and efficacy of OBX-115engineered tumor-infiltrating lymphocyte（TIL）cell therapy in patients（pts）with immune checkpoint inhibitor（ICI）-resistant advanced or metatic melanoma
Presenting Author:Sajeve S Thomas，Orlando Health Cancer Institute，Orlando，FL
后期：CT285，Tuesday April9,1:30 PM-5:00 PM PDT
标题：涡轮增压器（TIL）engineered with membrane-bound IL15（cytoTIL15cells）exhibit pharmacologicallly可调节的signal transduction in cis and trans
Presenting Author:Rachel Burga，Obsidian Therapeutics，Inc.，Cambridge，MA
后期：LB072，Sunday April7,1:30-5:00 PM PDT
标题：Tumor-infiltrating lymphocytes（TIL）engineered with regulatable membrane-bound IL15（mbIL15）and LIGHT（TNSF14）show enhanced efficacy in fibroblast-containing cold tumors
Presenting Author:Balazs Koscso，Obsidian Therapeutics，Inc.，Cambridge，MA
后期：LB065，Sunday April7,1:30-5:00 PM PDT
About OBX-115
Obsidian’slead investigational cytoTIL15™program，OBX-115，is anovered tumor-derived autologous T cell immunotherapy（tumor-infiltrating lymphocyte[TIL]cell therapy）armored with pharmacologicallly regulatable membrane-bound IL15（mbIL15）。OBX-115has the potential to become a meaningful therapeutic option for patients with advanced or metatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15and Obsidian’s proprietary，differentiated manufacturing process to enhance persistence，anti-tumor activity，and clinical safety of TIL cell therapy.OBX-115is being investigated in two ongoing and enrolling clinical trials in advanced or metastatic melanoma and NSCLC（NCT 05470283and，andNCT060613）。
About Obsidian Therapeutics
Obsidian Therapeutics，Inc.is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases。Obsidian’s proprietary cytoDRiVE®technology is designed to precisely regulate the timing and level of protein function byusing FDA-approved small-molecule drugs。Obsidian is headquartered in Cambridge，MA.The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals.For more information，please visitwww.obsidiantx.comand follow us onLinkedIn。
查看source version on businesswire.com：https://www.businesswire.com/news/home/20240305665630/en/
